Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron + OnabotulinumtoxinA in Refractory Overactive Bladder
NCT06438861Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in overactive bladder (OAB) comparing OnabotulinumtoxinA + Vibegron with OnabotulinumtoxinA + Placebo (2 arms). Primary endpoint: Urinary Urgency Incontinence episodes at 12 weeks. Planned start Jan 2025; status: withdrawn.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT06438861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438861.